Skip to content

Study · In vitro (cells) · 2024

2 results

KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.

Beretta GL, Alampi D, Corno C, Carenini N, Corna E, Perego P

International journal of molecular sciences6 May 2024Cited by 2 (Europe PMC)

PMID38732265 (opens in a new tab)PMCIDPMC11084743 (opens in a new tab)DOI10.3390/ijms25095048 (opens in a new tab)PepBankPUB-38732265
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Epigenetic alterations my play a role in the aggressive behavior of Non-Small Cell Lung Cancer (NSCLC). Treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA, vorinostat) has been reported to interfere with the proliferative and invasive potential of NSCLC cells. In addition, the DNA methyltransferase inhibitor azacytidine (AZA, vidaza) can modulate the levels of the metastasis suppressor KiSS-1. Thus, since cisplatin is still clinically available for NSCLC therapy, the aim of this study was to evaluate drug combinations between cisplatin and SAHA as well as AZA using cisplatin-sensitive H460 and -resistant H460/Pt NSCLC cells in relation to KiSS-1 modulation. An analysis of drug interaction according to the Combination-Index values indicated a more marked synergistic effect when the exposure to SAHA or AZA preceded cisplatin treatment with respect to a simultaneous schedule. A modulation of proteins involved in apoptosis (p53, Bax) was found in both sensitive and resistant cells, and compared to the treatment with epigenetic agents alone, the combination of cisplatin and SAHA or AZA increased apoptosis induction. The epigenetic treatments, both as single agents and in combination, increased the release of KiSS-1. Finally, the exposure of cisplatin-sensitive and -resistant cells to the kisspeptin KP10 enhanced cisplatin induced cell death. The efficacy of the combination of SAHA and cisplatin was tested in vivo after subcutaneous inoculum of parental and resistant cells in immunodeficient mice. A significant tumor volume inhibition was found when mice bearing advanced tumors were treated with the combination of SAHA and cisplatin according to the best schedule identified in cellular studies. These results, together with the available literature, support that epigenetic drugs are amenable for the combination treatment of NSCLC, including patients bearing cisplatin-resistant tumors.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In cisplatin-sensitive and cisplatin-resistant lung cancer cells, KP10 enhanced cisplatin-induced cell death.

    In plain wordsIn lab-grown lung cancer cells, kisspeptin‑10 made cisplatin kill more cells than cisplatin alone.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseCisplatin-induced cell death
    Study

    n: not reported in source

    Cisplatin-sensitive H460 and cisplatin-resistant H460/Pt NSCLC cells
    Comparator
    Cisplatin alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, the exposure of cisplatin-sensitive and -resistant cells to the kisspeptin KP10 enhanced cisplatin induced cell death.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 02LabEndogenous levelIn vitro (cells)Mechanism

    In lung cancer cells, the epigenetic agents SAHA and AZA, alone and with cisplatin, increased the release of KiSS-1.

    In plain wordsIn lab-grown lung cancer cells, two epigenetic drugs raised the cells' own KiSS-1 release.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseKiSS-1 release after SAHA or AZA
    Study

    n: not reported in source

    Cisplatin-sensitive H460 and cisplatin-resistant H460/Pt NSCLC cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The epigenetic treatments, both as single agents and in combination, increased the release of KiSS-1.

    This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.